Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
110Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-17.12M | $-1.57 |
| 2024 | $0.00 | $-20.78M | $-1930.92 |
| 2023 | $0.00 | $-15.96M | $-1.47 |
| 2022 | $0.00 | $-14.26B | $-1.31 |
| 2021 | $0.00 | $-12.36M | $-1.13 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.35 per share
Typical surprise +15.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.57 vs $-0.38miss
- Fri, May 15$-0.30 vs $-0.36beat
- Mon, Mar 30$-0.36 vs $-0.46beat
- Wed, Nov 12$-0.39 vs $-0.46beat
- Wed, Aug 13$-0.40 vs $-0.53beat
- Thu, May 15$-0.42 vs $-0.49beat
Estimates and results for LTRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
LTRNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·1d ago·Positive
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
View source ↗ - Newsbusinesswire.com·1d ago·Neutral
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
View source ↗